We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$146M
AUM Growth
-$65.3M
Cap. Flow
-$17.1M
Cap. Flow %
-11.73%
Top 10 Hldgs %
82.35%
Holding
48
New
3
Increased
1
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
SNOW icon
Snowflake
SNOW
+$3.04M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.98M
3
REPL icon
Replimune Group
REPL
+$1.33M
4
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$524K

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$5.98M
2
VIR icon
Vir Biotechnology
VIR
+$5.42M
3
BEAM icon
Beam Therapeutics
BEAM
+$3.15M
4
ILMN icon
Illumina
ILMN
+$2.74M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 97.27%
2 Technology 2.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.08B
$31M 21.3%
635,978
-132,730
-17% -$5.98M
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.6M 19.61%
225,688
-9,123
-4% -$1.05M
ILMN icon
3
Illumina
ILMN
$29.5B
$22M 15.09%
122,533
-10,744
-8% -$2.74M
EXAI
4
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$8.39M 5.76%
770,200
– –
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$8.33M 5.72%
47,096
– –
SLGC
6
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$7.67M 5.27%
1,696,558
– –
RANI icon
7
Rani Therapeutics
RANI
$94.8M
$5.1M 3.5%
493,584
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.1B
$3.48M 2.39%
114,380
-83,500
-42% -$2.53M
REPL icon
9
Replimune Group
REPL
$455M
$2.71M 1.86%
155,199
+80,720
+108% +$1.33M
SNOW icon
10
Snowflake
SNOW
$98.1B
$2.67M 1.83%
+19,210
New +$3.04M
INCY icon
11
Incyte
INCY
$25.8B
$2.61M 1.79%
34,391
– –
BOLT icon
12
Bolt Biotherapeutics
BOLT
$7.4M
$2.38M 1.64%
58,348
– –
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.29M 1.57%
+237,484
New +$2.98M
EAR
14
DELISTED
Eargo, Inc. Common Stock
EAR
$2.17M 1.49%
144,336
– –
TRDA icon
15
Entrada Therapeutics
TRDA
$254M
$2.11M 1.45%
173,582
– –
ONC
16
BeOne Medicines Ltd
ONC
$33.9B
$1.95M 1.34%
12,022
– –
OTIC
17
DELISTED
Otonomy, Inc.
OTIC
$1.77M 1.22%
851,080
– –
EXEL icon
18
Exelixis
EXEL
$13.9B
$1.34M 0.92%
64,200
– –
DBVT
19
DBV Technologies
DBVT
$813M
$946K 0.65%
37,095
– –
CCXI
20
DELISTED
ChemoCentryx, Inc.
CCXI
$888K 0.61%
35,830
– –
GRTX
21
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$797K 0.55%
613,223
– –
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$775K 0.53%
78,720
– –
PACB icon
23
Pacific Biosciences
PACB
$435M
$640K 0.44%
144,840
– –
STSA
24
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$592K 0.41%
142,900
– –
TSVT
25
DELISTED
2seventy bio
TSVT
$532K 0.37%
40,273
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q2 2022 Portfolio in Review

As of Q2 2022, Nan Fung Group Holdings held 48 positions worth $146M, down 31% from $211M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Nan Fung Group Holdings withdrew a net $17.1M in Q2 2022, closing 7 positions and reducing 5 holdings. Its most notable exit was Vir Biotechnology, an estimated $5.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Snowflake worth $2.67M.

  • Nan Fung Group Holdings's largest Q2 2022 buy was Snowflake: 19,210 shares worth $2.67M.
  • Nan Fung Group Holdings added most to Replimune Group in Q2 2022, an estimated $1.33M increase.
  • Nan Fung Group Holdings's biggest Q2 2022 reduction was Harmony Biosciences, cutting an estimated $5.98M.
  • Nan Fung Group Holdings fully exited Vir Biotechnology in Q2 2022, selling an estimated $5.42M.
  • Nan Fung Group Holdings's ten largest holdings make up 82% of its $146M portfolio in Q2 2022.
  • Nan Fung Group Holdings opened 3 new positions and closed 7 in Q2 2022.
  • Nan Fung Group Holdings's portfolio value fell 31% quarter-over-quarter to $146M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2022, filed 12 Aug 2022.